Almirall, S.A. (BME:ALM)

Market Cap	2.26B -4.3%
Revenue (ttm)	1.16B +9.8%
Net Income	59.13M +177.1%
EPS	0.28 +179.0%
Shares Out	217.78M
PE Ratio	37.64
Forward PE	22.22
Dividend	0.19 (1.80%)
Ex-Dividend Date	May 14, 2026

Volume	131,088
Open	10.52
Previous Close	10.50
Day's Range	10.38 - 10.54
52-Week Range	10.24 - 13.98
Beta	0.17
Analysts	Buy
Price Target	14.30 (+37.5%)
Earnings Date	Nov 9, 2026

About Almirall

Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal sys...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1943
• Employees: 2,097
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: ALM

Financial Performance

In 2025, Almirall's revenue was 1.11 billion, an increase of 12.51% compared to the previous year's 990.63 million. Earnings were 46.15 million, an increase of 354.85%.

Analyst Summary

According to 12 analysts, the average rating for ALM stock is "Buy." The 12-month stock price target is €14.30, which is an increase of 37.50% from the latest price.

Price Target

€14.30

(37.50% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 27, 2026

Data Sources Report a data error